TCT Group’s Targeted Cure Tec platform uses a minimally invasive endovascular catheter to deliver drugs directly to intracranial aneurysm sites, crossing the blood‑brain barrier for localized, sustained release. This enables neurovascular surgeons to treat acute aneurysmal subarachnoid hemorrhage with higher efficacy and lower systemic side effects, integrating with existing neurointerventional equipment.
Funding
Funding not disclosed
Founders
Product
Problem
Acute aneurysmal subarachnoid hemorrhage (aSAH) requires rapid treatment, but systemic drugs often fail to reach the brain in therapeutic concentrations or cause severe side effects, leading to poor neurological outcomes.
Solution
TCT Group’s Targeted Cure Tec platform delivers pharmacological agents directly to the site of aSAH via a minimally invasive endovascular catheter. The device navigates the cerebral vasculature, crosses the blood‑brain barrier, and releases the drug locally in a controlled, sustained manner. This approach maximizes therapeutic efficacy at the injury site while minimizing systemic exposure and associated adverse effects. By integrating catheter technology with specialized drug formulations, the system provides clinicians with precise dosing control throughout the critical post‑bleed period.
Target Audience
Primary customers are neurovascular surgeons and hospital centers treating aSAH, as well as pharmaceutical companies seeking targeted delivery solutions for central nervous system therapeutics.
Features
- Endovascular catheter system designed for navigation to intracranial aneurysm sites
- Capability to cross the blood‑brain barrier and deposit drugs directly at the lesion
- Controlled, sustained-release formulation enabling prolonged therapeutic exposure
- Minimally invasive deployment reduces procedural risk compared with open surgery
- Compatibility with existing neurointerventional suites and imaging workflows